Kirsten Bibbins-Domingo
0:00 ↗
Intro: From the JAMA Network, this is JAMA Clinical Reviews, interviews and ideas about innovations in medicine, science, and clinical practice.
Hello, and welcome to our listeners around the world. I'm Dr. Kirsten Bibbins-Domingo, the Editor in Chief of JAMA and the JAMA Network. Very occasionally, we depart from the traditional format of the JAMA Clinical Reviews Podcast to bring you information that is timely, thought-provoking, and has the potential to shape clinical practice.
I recently spoke with Mark Cuban, an entrepreneur and the co-founder of the Mark Cuban Cost Plus Drug Company, an online pharmacy that sells medications directly to consumers at the acquisition cost from the manufacturer plus a 15% markup. The company primarily sells generic medications and for prices that are significantly lower than many traditional pharmacies. Cuban has been outspoken about price transparency and cost-based prices, and his work has challenged the role of pharmacy benefit managers, insurance formularies, and opaque pricing practices that shape how most Americans access prescription drugs.
Throughout this interview, Mr. Cuban uses acronyms for many processes and entities in health insurance, including PBMs, which stands for pharmacy benefit managers. The full term for each of these acronyms can be found in the transcript.
Mark, there is a lot I'd like to discuss today, but we should probably start by congratulating you and your Indiana Hoosiers on their incredible national championship run.
Thank you. Hoosiers, what a weekend. Oh my goodness. I never did I imagine, so thank you.
Kirsten Bibbins-Domingo
1:53 ↗
Wonderful, wonderful. So we're going to go to a lot of places here today, and this can be dense stuff, but I know you have the experience with this Cost Plus Drug Company, and you've basically shown with success there that many generic medications can be sold at a fraction of current prices. In healthcare terms, what does this tell us about the market?
I mean, it tells you that it's not an efficient market. The fact that you mentioned us as having generics when our mission is to sell every drug we're legally allowed to, suggesting that we don't have all that many brands, and it's true. We have some brands and it's growing, but the question then becomes, why don't we have all brands? Why don't we have all specialty medications? And the reason is the big PBMs (pharmacy benefit managers) owned by the big three insurance companies dominate the industry and their formularies dictate what's paid for and what's not paid for. And if you're a pharmaceutical manufacturer, regardless of what you make, if it's branded, you have to pay, you have to bid in that auction to get on the formulary. Because if you're not on the formulary, those 300 million lives that are covered by insurance probably aren't going to be allowed to buy your medication.
Kirsten Bibbins-Domingo
3:06 ↗
So it's not something specific to generics then?
No, no, not at all. No. No. We'd love to sell every single brand and we do it the exact same way if we could. But what's happened, and we'll talk to those brand manufacturers and we'll say, "Why can't we buy from you? Or why can't we get the same rebates? Why can't we get the same type of deal?" And they'll tell us because if they do it, then those big PBMs and the insurance companies that own them will reduce the positioning of their entire portfolio on those formularies, which could cost them tens of millions, hundreds of millions of dollars or more. And so they're like, "Mark, we love what you're doing. We're trying to find a way to work with you, but we just can't." I spoke to one CEO of one of the companies a month ago maybe, and I said, "How many lives do we need to have covered out of the 180 million before you would say you'll work directly with us?" Half. That's a big number.
Kirsten Bibbins-Domingo
4:04 ↗
Yeah.
That's a big number. So the point is, we no longer have an efficient market. In an efficient market, it'd be like, "Mark, we'll charge you more, but we'll sell. We'll sell through you." It's just like you're selling hammers, you open up a new hardware store, sure we'll sell you our hammers. You might not get the same price as Walmart, but we'll sell you our hammer. So we've got a system right now that is completely inefficient. And what I've learned over the past four years, and literally this week is the fourth anniversary of Cost Plus Drugs, I always looked at it as specific to PBMs. Then what I realized is these big PBMs either own or are all owned by big insurance companies, and they all act the same kind of way.
Kirsten Bibbins-Domingo
4:50 ↗
So what would have to change, and is that possible to shift that to be a more efficient market?
One of two things. First, the most direct path is to require the big insurance companies, the biggest three insurance companies to divest non-insurance assets. If you don't get them to divest, they effectively have... There's regulatory capture and there's scale capture. And scale capture is we're so big, nobody really understands how the money flows and how the pieces are interrelated so that they really define the rules of all the economics of the healthcare industry. They literally define the rules. Divesting, not just PBMs, but all their subsidiaries that are not insurance specific.
Kirsten Bibbins-Domingo
5:32 ↗
I see. Yeah.
Well, if you happen to be a big insurance company and you own a hospital or a provider or an oncology center or an infusion center or a PBM or physician's practices, and we need to make this just like AT&T in 1984 where they controlled all telecommunications. Literally, there's one big healthcare company that's got 2,600 subsidiaries. Their intercompany transfers are $200 billion. That's like 0.6% of the GDP (gross domestic product) of this country. That's how much control and influence they have. There's just no way for that market to be efficient. And then they use that because they can left pocket, right pocket things. "Hey, we're just charging you," and they may or may not mark it up. "We're just charging you what the physician charged us or what the provider charged us or what the center charged us and we're just passing it along," and the employer has no idea that they're getting marked up in a way that is just going right to the insurer. Now that's part one. You break them up. And if I was a Democrat or a Republican, that would be what I was pushing right now.
The second thing is educate employers. There's 160 million plus beneficiaries in self-pay plans, right? And some of them are public, some of them are private. I'll walk into the CEO of a company. I can walk in and within five minutes give you 20 things that tell you how you're getting ripped off. So for instance, right now we just rolled over to a new year. I'll go to the pharmacy side and let's just say that you happen to use a branded medication. I don't know what your deductibles are for your employees, but for easy numbers, let's just say it's $2,000. And so if you happen to be prescribed a branded medication that has a retail price of $600, Eliquis was $609 until they just changed it, right? Well, just say it's Eliquis and you're paying $609. You have to pay that full retail price until you reach-
Kirsten Bibbins-Domingo
7:45 ↗
My deductible. Right.
Right? So where does that money go? Well, for a branded medication like Eliquis was at $600, 50% of that is rebate. So your beneficiary plan holder is paying full retail price, which first of all means that PBM that you hired is the worst negotiator on the planet, even though they sell themselves as being better for reducing drug prices because every single one of your beneficiaries, your members that is using a branded medication is paying full retail and 50% of that give or take, depending on what the rebate is going to the PBM who keeps, let's say, 10% of it and sends it to you as your rebate. And I'll sit with the CEO and tell them, "Do you really understand now that your sickest employees and those with the most chronic illnesses that need medications are writing your company a check through those rebates?" And then they'll talk to their HR person. They'll be in a panic because I'm like, "Look, not only are they writing you a check, but there are going to be times when they don't buy their medications because their take home pay may be $30,000 a year and they couldn't afford the high premium, so they took the higher deductible and so they can't afford it and somebody, God forbid, may drop dead because you hired a PBM that wanted to charge them full retail price and you did nothing about it."
Kirsten Bibbins-Domingo
9:13 ↗
So you want to get employers, they're the purchasers to be involved because you think they can negotiate better.
Yeah, because they have no clue what they're doing. In many cases, they're using consultants or brokers who are ripping them off even further. Some of those consultants are getting fees from the PBM/insurance companies and now the PBMs are getting smarter. So it doesn't come from the PBM. It comes from a subsidiary or somewhere else within the empire, if you will, of subsidiaries. And so as an employer, you don't know these things. Particularly for a CEO. It's not your core competency to understand your HR benefits, particularly how people are paying for brand medications within their deductible phase. And so I'll walk in there and start educating them on how that works. Your second-largest expense item after payroll, and you have no clue where the expenses come from.
So tell me this, do you have examples where employers have then now successfully negotiated after you've coached them through this?
Oh yeah. You've seen 7-Eleven, I've worked closely with them, you've seen... I don't want to say I worked closely with Genentech and Eli Lilly, but I had conversations going through all this with them and then they took the ball and ran with it. There's other companies that are doing the same thing. So it's happening, but it can't happen fast enough. And so I've had a big enough mouth and screamed loudly enough that you're starting to see PBMs talking about transparency and talking about how they're going to do pass through of all the rebates, but it's a lie because they'll just move it to something else. So while they may do a better job of passing through the rebates, they'll actually charge bigger fees to the pharmaceutical manufacturers and bigger fees to the employers and the employers won't even know it.
Yeah. Yeah. So you mentioned Eli Lilly as a company you've talked to. Eli Lilly and other manufacturers are now marketing and distributing drugs directly to consumers as well through platforms like Lilly Direct, often paired with telehealth. So they're also controlling the prescriber. From your perspective, is this a good thing and will this help us with the pricing issue?
Yes. And I'll tell you why.
One thing that's missing in the supply chain of Lilly Direct, Novo [Nordisk], BMS (Bristol Myers Squibb), and the others, there's no PBM.
There's no PBM in the middle of it at all. What's the difference between the pricing that European countries get versus America? They don't use PBMs over there. And the amount, if you just looked at the net price that Lilly, Genentech, BMS, Pfizer, the net price they get for their branded medications and specialty drugs, if you'd mark that up 5, 10, 15%, whatever it is, and left out the PBMs, we'd be having a whole different conversation about the price. If it was able to come to cost plus drugs, even if we didn't get as good a price as the big PBMs and we only marked it up 15% and it was transparent, it would be a whole different conversation.
So one of the things that does strike me as different though is that when you have someone like Eli Lilly as the producer and the distributor controls the drugs, and then really through telehealth controls the ability to have access to the drugs, from a consumer perspective, it certainly is attractive. I think those of us who sit on the physician side worry a little bit about that.
And rightfully so, right? But there's still doctors on the other side of that video.
So you think that's ultimately a force for good, and you're not worried that you're just building up a whole nother system where they control everything about the pricing of their product, which they would.
Definitely a risk. So it's the lesser of two evils. I don't want to... Maybe that's not the right word, but on one hand, you have the PBMs owned by the big insurance companies who I truly believe are the cause of all these problems. And then on the other hand, because of the structure and the amount of money they control, the brand manufacturers are trying to figure out ways to work around them. And in the short period of time, it may not be perfect, but it's a step. And let me just tell you, knowing what I know about some of them, they make less money, a lot less money on the direct to consumer. And in some cases, there's examples where they'll actually lose money, but they're taking these steps to try to change the game.
Well, but they're not in the charity business. They're presumably win on scale, right?
Well, no. I mean, yes, on scale, but more thinking strategically down the line. So even though I may not have the optimal scenario today in 2028, 2029, hopefully we'll have that scale and we may have bumped out the PBMs at some level. And if they do that, I'm willing to take some of their problems.
I see. I see. So we're united in the PBMs are bad, the insurance companies are sort of overgrowing and that's the big cause in the-
Right. In my mind, that's the underpinning of the problem on the economic side of healthcare. And that influences the care side of healthcare as well, because they're the ones giving you seven minutes per patient. They're the ones that are telling you all the paperwork you have to fill. They're the ones that are having the pre-auth (pre-authorization) denials and having you spend multiple hours for however many weeks in front of a committee. You get my point, right? They introduce these inefficiencies that cost you money and that can't continue. That's a problem.
Yeah. Well, I've heard you describe physicians as good actors in a broken system. And what types of things in our either drug or just the broader insurance market really do you believe interfere with the doctor's ability to take care of patients?
All of it. And on the CMS side as well, I think doctors are underpaid. I think they're rushed. I want my doctors golfing on Wednesday. I like the concept of direct primary care, but it's kind of conflicted because it's hard for people to understand where it fits and everything. But when you look at insurance and the way it's designed, that's the start of the problem. So let's work this through, use your company again as an example. So you go to an insurance company and some of them bid and you pick one and they come back to you with different plans and then you decide which of those plans you think best fit what you can afford based off of what the company contributes and what you think that your employees and their families will appreciate and be able to tolerate in many cases and gain the care they need based off the circumstances that you understand, right? So it starts there. And in those plans that they offer, there's lower premiums, higher deductibles, because some people can't afford their premiums or maybe they're healthier and vice versa, higher premiums, lower deductibles. In all cases, those deductibles are the gatekeepers for the out of pocket, not only to the member, but also to the insurance company. Because the higher the deductible, the greater the risk to the member to be able to pay. And if they can't pay their deductible, either the insurance company benefits by not having to do anything, right?